BioFocus

Type: Company
Name: BioFocus
First reported Oct 17 2014 - Updated Oct 18 2014 - 1 reports

MedImmune teams with UK academics on neurodegenerative disease research

MedImmune’s neurodegenerative disease partnership with the University of Cambridge is about working with “great scientists with great brains” according to a spokeswoman for parent company, AstraZeneca.The three-year R&D deal will aim to plug gaps in drug ... [Published In-Pharmatechnologist - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Galapagos appoints Bart Filius as chief financial officer

Bart Filius has been appointed as chief financial officer at Belhium-based biotech firm Galapagos.He will start in the role from December 1, 2014, joining the executive committee of the company and will be responsible for finance, investor relations, ... [Published PMLive - Oct 16 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Global High Throughput Screening (HTS) Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Danaher, PerkinElmer, Sigma-Aldrich and Thermo Fisher

DUBLIN , Oct. 14, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global High Throughput Screening (HTS) Market 2014-2018" report to their offering.High throughput screening (HTS) is a technology of screening and analyzing ... [Published Market Pulse Navigator - Oct 14 2014]
First reported Oct 13 2014 - Updated Oct 13 2014 - 1 reports

With help from Charles River, AstraZeneca expands its respiratory pipeline

AstraZeneca ($AZN) is moving forward with a respiratory candidate developed alongside Charles River Laboratories' ($CRL) discovery business, a milestone the CRO says affirms its investments in the space.The drug, an oral respiratory treatment, is the ... [Published Fierce CRO - Oct 13 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

Global High Throughput Screening (HTS) Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Danaher, PerkinElmer, Sigma-Aldrich and Thermo Fisher

Research and Markets (http://www.researchandmarkets.com/research/qzqwwb/global_high) has announced the addition of the "Global High Throughput Screening (HTS) Market 2014-2018" report to their offering. High throughput screening (HTS) is a technology ... [Published Individual.com - Oct 09 2014]
First reported Oct 07 2014 - Updated Oct 07 2014 - 5 reports

Charles River, AZ Alliance Delivers Respiratory Candidate

Charles River Labs’ drug discovery collaboration with AstraZeneca has delivered an undisclosed, oral respiratory candidate for progression into preclinical development.AstraZeneca and BioFocus, now part of Charles River Discovery Services, have been working ... [Published Contract Pharma - Oct 07 2014]
First reported Oct 04 2014 - Updated Oct 04 2014 - 1 reports

OMICS to organise 3rd biosimilars-2014 from October 27 to 29 at HICC, Hyderabad

OMICS International to organise third international conference and exhibition on biowaivers, biologics and biosimilars from October 27 to 29 at HICC, Hyderabad. Through this event they aim to explore the current challenges and opportunities in making ... [Published PharmaBiz - Oct 04 2014]
Entities: biosimilar, OMICS, Hyderabad
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Rules for drug discovery: can simple property criteria help you to find a drug? Spring 14

The years since the publication of Lipinski’s Rule of Five (Ro5)1 in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by what Kenny and Montanari have termed “Ro5 envy”2, these rules are usually ... [Published Drug Discovery World - Sep 15 2014]

Quotes

"We are extremely pleased AstraZeneca chose to partner with Charles River for its early drug-discovery work," Smith said in a statement. "The recognition this project received from the AstraZeneca Innovative Medicines team is a testament to our collaborative approach to partner programs."

More Content

All (12) | News (9) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MedImmune teams with UK academics on neurodegen... [Published In-Pharmatechnologist - Oct 17 2014]
Galapagos appoints Bart Filius as chief financi... [Published PMLive - Oct 16 2014]
Global High Throughput Screening (HTS) Market 2... [Published Market Pulse Navigator - Oct 14 2014]
With help from Charles River, AstraZeneca expan... [Published Fierce CRO - Oct 13 2014]
Global High Throughput Screening (HTS) Market 2... [Published Individual.com - Oct 09 2014]
Charles River, AZ Alliance Delivers Respiratory... [Published Contract Pharma - Oct 07 2014]
Charles River Laboratories (Massachusetts)???s ... [Published BioSpace - Oct 07 2014]
Charles River’s Early Drug Discovery Collaborat... [Published EON Science - Oct 07 2014]
Charles River’s Early Drug Discovery Collaborat... [Published Business Wire Science: Science News - Oct 07 2014]
Charles River’s Early Drug Discovery Collaborat... [Published Business Wire Health News - Oct 07 2014]
OMICS to organise 3rd biosimilars-2014 from Oct... [Published PharmaBiz - Oct 04 2014]
Rules for drug discovery: can simple property c... [Published Drug Discovery World - Sep 15 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Charles River’s Early Drug Discovery Collaborat... [Published EON Science - Oct 07 2014]
WILMINGTON, Mass.--(EON: Enhanced Online News)--Charles River Laboratories International, Inc. announced today that its integrated drug discovery collaboration with AstraZeneca has delivered an oral respiratory candidate drug for progression into preclinical ...
Charles River’s Early Drug Discovery Collaborat... [Published Business Wire Science: Science News - Oct 07 2014]
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. announced today that its integrated drug discovery collaboration with AstraZeneca has delivered an oral respiratory candidate drug for progression into preclinical development. ...
Charles River’s Early Drug Discovery Collaborat... [Published Business Wire Health News - Oct 07 2014]
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. announced today that its integrated drug discovery collaboration with AstraZeneca has delivered an oral respiratory candidate drug for progression into preclinical development. ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.